Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis

References

• SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin201868173029313949
   PubMed Web of Science ®Google Scholar
• LiuYThe context of prostate cancer genomics in personalized medicineOncol Lett20171353347335328521441
   PubMed Web of Science ®Google Scholar
• LiDYHaoXYMaTMDaiHXSongYSThe prognostic value of platelet-to-lymphocyte ratio in urological cancers: a meta-analysisSci Rep2017711538729133845
   PubMedGoogle Scholar
• LiDLvHHaoXDongYDaiHSongYPrognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysisOncotarget2017848844498445829137438
   PubMedGoogle Scholar
• GraffREPetterssonALisRTDietary lycopene intake and risk of prostate cancer defined by ERG protein expressionAm J Clin Nutr2016103385186026817504
   PubMed Web of Science ®Google Scholar
• CochettiGPoliGGuelfiGBoniAEgidiMGMeariniEDifferent levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic roleOnco Targets Ther201697545755328008272
   PubMed Web of Science ®Google Scholar
• ZhangMChenLYuanZCombined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkersDiscov Med20162212228129528009970
   PubMed Web of Science ®Google Scholar
• SalviSGurioliGde GiorgiUCell-free DNA as a diagnostic marker for cancer: current insightsOnco Targets Ther201696549655927822059
   PubMed Web of Science ®Google Scholar
• SharmaUPalDPrasadRAlkaline phosphatase: an overviewIndian J Clin Biochem201429326927824966474
   PubMedGoogle Scholar
• FanYJinXJiangMFangNElevated serum alkaline phosphatase and cardiovascular or all-cause mortality risk in dialysis patients: A meta-analysisSci Rep2017711322429038525
   PubMedGoogle Scholar
• RenH-YSunL-LLiH-YYeZ-MPrognostic significance of serum alkaline phosphatase level in osteosarcoma: a meta-analysis of published dataBiomed Res Int201520151016083526618165
   PubMedGoogle Scholar
• GrootMTBoeken KrugerCGPelgerRCUyl-de GrootCACosts of prostate cancer, metastatic to the bone, in The NetherlandsEur Urol200343322623212600424
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementPLoS Med200967e100009719621072
   PubMed Web of Science ®Google Scholar
• StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360520652370
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: Is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• HalabiSLinCYSmallEJPrognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapyJ Natl Cancer Inst2013105221729173724136890
   PubMedGoogle Scholar
• GoldkornAElyBQuinnDICirculating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerJ Clin Oncol201432111136114224616308
   PubMed Web of Science ®Google Scholar
• SchellhammerPFChodakGWhitmoreJBSimsRFrohlichMWKantoffPWLower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trialUrology20138161297130223582482
   PubMed Web of Science ®Google Scholar
• HumphreyPAHalabiSPicusJPrognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 150005/9480Clin Genitourin Cancer20064426927416729910
   PubMed Web of Science ®Google Scholar
• HalabiSLinCYKellyWKUpdated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancerJ Clin Oncol201432767167724449231
   PubMed Web of Science ®Google Scholar
• QuYyDaiBKongYYPrognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapyAsian J Androl201315111011523147466
   PubMed Web of Science ®Google Scholar
• MikahPKrabbeLMEminagaODynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancerBMC Cancer201616121426975660
   PubMedGoogle Scholar
• KlaffRVarenhorstEBerglundAClinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patientsScand J Urol201650535235927603423
   PubMed Web of Science ®Google Scholar
• MiyamotoSItoKMiyakuboMImpact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapyProstate Cancer Prostatic Dis2012151758621986985
   PubMed Web of Science ®Google Scholar
• KitaYShimizuYInoueTKambaTYoshimuraKOgawaOReduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patientsInt J Clin Oncol201318471872322791141
   PubMed Web of Science ®Google Scholar
• BilenMAHessKRSubudhiSKClinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyCancer Chemother Pharmacol201780358358928730293
   PubMed Web of Science ®Google Scholar
• OmlinAPezaroCMukherjiDImproved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomogramsEur Urol201364230030623313031
   PubMed Web of Science ®Google Scholar
• NakashimaJOzuCNishiyamaTPrognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapyUrology200056584384711068314
   PubMed Web of Science ®Google Scholar
• TempletonAJPezaroCOmlinASimple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratioCancer2014120213346335224995769
   PubMed Web of Science ®Google Scholar
• van SoestRJNieuweboerAJMde MorréeESThe influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancerEur J Cancer201551172562256926278646
   PubMed Web of Science ®Google Scholar
• SonpavdeGPondGRArmstrongAJPrognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancerClin Genitourin Cancer201412531732424806399
   PubMed Web of Science ®Google Scholar
• HalabiSSmallEJKantoffPWPrognostic model for predicting survival in men with hormone-refractory metastatic prostate cancerJ Clinic Oncol200321712321237
   PubMed Web of Science ®Google Scholar
• ShiotaMYokomizoAAdachiTThe oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancerJpn J Clin Oncol201444986086724951829
   PubMed Web of Science ®Google Scholar
• OhWKMiaoRVekemanFPatient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community settingMed Oncol201734916028795333
   PubMed Web of Science ®Google Scholar
• BrassoKChristensenIJJohansenJSPrognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinomaProstate200666550351316372331
   PubMed Web of Science ®Google Scholar
• ChiKNKheohTRyanCJA prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelAnn Oncol201627345446026685010
   PubMed Web of Science ®Google Scholar
• NozawaMHaraIMatsuyamaHSignificance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasisWorld J Urol20153391263126825354720
   PubMed Web of Science ®Google Scholar
• PientaKJRedmanBGBandekarRA phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancerUrology19975034014079301705
   PubMed Web of Science ®Google Scholar
• ReynardJMPetersTJGillattDProstate-specific antigen and prognosis in patients with metastatic prostate cancer - a multivariable analysis of prostate cancer mortalityBr J Urol19957545075157540483
   PubMedGoogle Scholar
• ThataiLCBanerjeeMLaiZVaishampayanURacial disparity in clinical course and outcome of metastatic androgen-independent prostate cancerUrology200464473874315491712
   PubMed Web of Science ®Google Scholar
• VesalainenSLipponenPTaljaMSyrjänenKBiochemical parameters as prognostic factors in prostatic adenocarcinomaActa Oncol19953415359
   PubMed Web of Science ®Google Scholar
• EtchebehereECMiltonDRAraujoJCSwanstonNMMacapinlacHARohrenEMFactors affecting 223Ra therapy: clinical experience after 532 cycles from a single institutionEur J Nucl Med Mol Imaging201643182026416392
   PubMed Web of Science ®Google Scholar
• GeorgeDJHalabiSShepardTFPrognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480Clin Cancer Res2001771932193611448906
   PubMed Web of Science ®Google Scholar
• ButtiglieroCPisanoCTucciMPrognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxelActa Oncol201756455556228068151
   PubMed Web of Science ®Google Scholar
• ShigetaKKosakaTKitanoSHigh absolute monocyte count predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapyAnn Surg Oncol201623124115412227364499
   PubMed Web of Science ®Google Scholar
• WyattRBSanchez-OrtizRFWoodCGRamirezELogothetisCPettawayCAPrognostic factors for survival among Caucasian, African-American and Hispanic men with androgen-independent prostate cancerJ Natl Med Assoc200496121587159315622688
   PubMed Web of Science ®Google Scholar
• RamankulovALeinMKristiansenGLoeningSAJungKPlasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancerProstate200767333034017192877
   PubMed Web of Science ®Google Scholar
• SonpavdeGPondGRBerryWRSerum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapyUrol Oncol201230560761320888271
   PubMed Web of Science ®Google Scholar
• HalabiSSmallEJVogelzangNJBarrierRCGeorgeSLGilliganTDImpact of race on survival in men with metastatic hormone-refractory prostate cancerUrology200464221221715302462
   PubMed Web of Science ®Google Scholar
• OhWKVargasRJacobusSElevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patientsCancer2011117351752520862742
   PubMed Web of Science ®Google Scholar
• IzumiKMizokamiAItaiSIncreases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasisBJU Int2012109339440021599822
   PubMed Web of Science ®Google Scholar
• HammerichKHDonahueTFRosnerILAlkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancerUrologic Oncology201735460.e21e28
   PubMed Web of Science ®Google Scholar
• CookRJColemanRBrownJMarkers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancerClin Cancer Res200612113361336716740758
   PubMed Web of Science ®Google Scholar
• ParkJMNamJSNaWPrognostic value of body mass index in Korean patients with castration-resistant prostate cancerKorean J Urol2012531176176523185667
   PubMedGoogle Scholar
• YamadaYNaruseKNakamuraKInvestigation of risk factors for prostate cancer patients with bone metastasis based on clinical dataExp Ther Med20101463563922993586
   PubMed Web of Science ®Google Scholar
• KamiyaNSuzukiHYanoMImplications of serum bone turnover markers in prostate cancer patients with bone metastasisUrology20107561446145120206975
   PubMed Web of Science ®Google Scholar
• MohammedAAEl-TanniHGhanemHMImpact of body mass index on clinico-pathological parameters and outcome in patients with metastatic prostate cancerJ Egypt Natl Canc Inst201527315515926227217
   PubMedGoogle Scholar
• AkimotoSInomiyaHAkakuraKShimazakiJItoHPrognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphataseJpn J Clin Oncol19972742582629379515
   PubMed Web of Science ®Google Scholar
• KooKCParkSUKimKHPredictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levelsProstate Int201531101526157761
   PubMed Web of Science ®Google Scholar
• KatoMTsuzukiTKimuraKThe presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentationMod Pathol201629216617326743470
   PubMed Web of Science ®Google Scholar
• D’AmicoAVChenMHCoxMCDahutWFiggWDProstate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancerUrology200566357157616140080
   PubMed Web of Science ®Google Scholar
• BandoYHinataNTerakawaTActivity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agentsMed Oncol201734916328819719
   PubMed Web of Science ®Google Scholar
• PelgerRCLycklamaANijeholtGAZwindermanAHPapapoulosSEHamdyNAThe flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinomaJ Urol199615611221268648772
   PubMed Web of Science ®Google Scholar
• HanKSHongSJSerum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasisJ Cancer Res Clin Oncol2014140101769177624858569
   PubMed Web of Science ®Google Scholar
• GoodmanOBSymanowskiJTLoudyiAFinkLMWardDCVogel-zangNJCirculating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancerClin Genitourin Cancer201191313821705286
   PubMed Web of Science ®Google Scholar
• MatsuyamaHShimabukuroTHaraICombination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancerInt J Clin Oncol201419594695424272390
   PubMed Web of Science ®Google Scholar
• FizaziKMassardCSmithMBone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancerEur Urol2015681425025449207
   PubMed Web of Science ®Google Scholar
• RahbarKBoegemannMYordanovaAPSMA targeted radio-ligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survivalEur J Nucl Med Mol Imaging2018451121929026946
   PubMed Web of Science ®Google Scholar
• SartorOColemanRENilssonSAn exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223Ann Oncol20172851090109728453701
   PubMed Web of Science ®Google Scholar
• NowsheenSAzizKPanayiotidisMIGeorgakilasAGMolecular markers for cancer prognosis and treatment: have we struck gold?Cancer Lett20123271–214215222120674
   PubMed Web of Science ®Google Scholar
• LiuFZhaoJXieJPrognostic risk factors in patients with bone metastasis from colorectal cancerTumour Biol201637121612716134
   Google Scholar
• LimSMKimYNParkKHBone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patientsBMC Cancer201616138527377907
   PubMedGoogle Scholar
• HuangPLanMPengAFSerum calcium, alkaline phosphatase and hemoglobin as risk factors for bone metastases in bladder cancerPLoS One2017129e018383528902911
   PubMed Web of Science ®Google Scholar